Skip to main content
رجوع
SHEZF logo

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

جودة البيانات: 100%
ذروة شراء
SHEZF
OTC Healthcare Drug Manufacturers - Specialty & Generic
KWD 0.47
KWD 0.00 (0.00%)
القيمة السوقية: 690.29M
نطاق اليوم
KWD 0.47 KWD 0.72
نطاق 52 أسبوعًا
KWD 0.47 KWD 0.72
حجم التداول
25
متوسط 50 يوم / 200 يوم
KWD 0.47 / KWD 0.47
الإغلاق السابق
KWD 0.47

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 1.1 0.4
P/B 0.1 2.9
ROE % 5.4 3.9
Net Margin % 12.3 3.8
Rev Growth 5Y % -0.2 10.0
D/E 0.3 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.526
KWD 0.526 – KWD 0.526
 6.2 B 1
FY2026 KWD 0.487
KWD 0.487 – KWD 0.487
 5.8 B 1

النقاط الرئيسية

Revenue declined -0.24% annually over 5 years
Debt/Equity of 0.25 — conservative balance sheet
Generating 1.99B in free cash flow
P/E of 1.07 — trading at a low valuation
Cash machine — converts 307.91% of earnings into free cash flow
Capital efficient — spends only 3.84% of revenue on capex

النمو

Revenue Growth (5Y)
-0.24%
Revenue (1Y)-3.03%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
5.38%
ROIC3.68%
Net Margin12.25%
Op. Margin14.04%

الأمان

Debt / Equity
0.25
Current Ratio2.60
Interest Coverage5.25

التقييم

P/E Ratio
1.07
P/B Ratio0.06
EV/EBITDA2.67
Dividend Yield0.03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3.03% Revenue Growth (3Y) -14.12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) -5.71%
Revenue Growth (5Y) -0.24% Earnings Growth (5Y) -10.86%
Profitability
Revenue (TTM) 5.28B Net Income (TTM) 646.74M
ROE 5.38% ROA 3.73%
Gross Margin 33.26% Operating Margin 14.04%
Net Margin 12.25% Free Cash Flow (TTM) 1.99B
ROIC 3.68% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.25 Current Ratio 2.60
Interest Coverage 5.25 Dividend Yield 0.03%
Valuation
P/E Ratio 1.07 P/B Ratio 0.06
P/S Ratio 0.13 PEG Ratio -0.04
EV/EBITDA 2.67 Dividend Yield 0.03%
Market Cap 690.29M Enterprise Value 1.98B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 5.28B 5.45B 7.16B 6.37B 5.33B
Net Income 646.74M -783.26M 727.43M 240.79M 1.02B
EPS (Diluted) 0.44 -0.53 0.50 0.16 0.76
Gross Profit 1.76B 944.92M 2.33B 2.03B 2.09B
Operating Income 741.31M -860.91M 828.62M 227.47M 1.33B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 17.34B 19.20B 20.81B 19.11B 19.03B
Total Liabilities 5.14B 7.22B 8.41B 7.58B 7.34B
Shareholders' Equity 12.15B 11.91B 12.31B 11.41B 11.57B
Total Debt 2.98B 3.78B 6.46B 5.65B 5.65B
Cash & Equivalents 1.69B 1.85B 2.14B 2.94B 2.71B
Current Assets 9.62B 10.60B 12.39B 10.77B 9.13B
Current Liabilities 3.70B 4.99B 5.58B 4.79B 3.61B

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#286 of 827
51
Value Defensive Investing (Benjamin Graham)
#175 of 709
45

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026